Saltar a la navegació principal Saltar a la cerca Vés al contingut principal

Enhancing the Capabilities of Continuous Glucose Monitoring With a Predictive App

  • Pau Herrero
  • , Magí Andorrà
  • , Nils Babion
  • , Hendericus Bos
  • , Matthias Koehler
  • , Yannick Klopfenstein
  • , Eemeli Leppäaho
  • , Patrick Lustenberger
  • , Ajandek Peak
  • , Christian Ringemann
  • , Timor Glatzer
  • Roche Diabetes Care Spain SL.
  • Roche Diabetes Care Deutschland GmbH
  • IBM

Producció científica: Contribució a revistaArticle científicAvaluat per experts

26 Cites (Scopus)

Resum

Background: Despite abundant evidence demonstrating the benefits of continuous glucose monitoring (CGM) in diabetes management, a significant proportion of people using this technology still struggle to achieve glycemic targets. To address this challenge, we propose the Accu-Chek® SmartGuide Predict app, an innovative CGM digital companion that incorporates a suite of advanced glucose predictive functionalities aiming to inform users earlier about acute glycemic situations. Methods: The app’s functionalities, powered by three machine learning models, include a two-hour glucose forecast, a 30-minute low glucose detection, and a nighttime low glucose prediction for bedtime interventions. Evaluation of the models’ performance included three data sets, comprising subjects with T1D on MDI (n = 21), subjects with type 2 diabetes (T2D) on MDI (n = 59), and subjects with T1D on insulin pump therapy (n = 226). Results: On an aggregated data set, the two-hour glucose prediction model, at a forecasting horizon of 30, 45, 60, and 120 minutes, achieved a percentage of data points in zones A and B of Consensus Error Grid of: 99.8%, 99.3%, 98.7%, and 96.3%, respectively. The 30-minute low glucose prediction model achieved an accuracy, sensitivity, specificity, mean lead time, and area under the receiver operating characteristic curve (ROC AUC) of: 98.9%, 95.2%, 98.9%, 16.2 minutes, and 0.958, respectively. The nighttime low glucose prediction model achieved an accuracy, sensitivity, specificity, and ROC AUC of: 86.5%, 55.3%, 91.6%, and 0.859, respectively. Conclusions: The consistency of the performance of the three predictive models when evaluated on different cohorts of subjects with T1D and T2D on different insulin therapies, including real-world data, offers reassurance for real-world efficacy.

Idioma originalAnglès
Pàgines (de-a)1014-1026
Nombre de pàgines13
RevistaJournal of Diabetes Science and Technology
Volum18
Número5
DOIs
Estat de la publicacióData de publicació - de set. 2024
Publicat externament

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

  1. ODG 3 – Salut i benestar
    ODG 3 – Salut i benestar

Fingerprint

Navegar pels temes de recerca de 'Enhancing the Capabilities of Continuous Glucose Monitoring With a Predictive App'. Junts formen un fingerprint únic.

Com citar-ho